Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Rani Therapeutics HoldingsRANI +2.79%31 3-Year EBITDA Growth Rate is 39.90% as of Mar. 2026. GuruFocus rates RANI with a GF Score™ of 31/100. The stock has 3 warning signs investors should review. Among 1,131 Biotechnology companies, Rani Therapeutics Holdings ranks better than 78.16% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 39.90% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 9.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 7 years, the highest 3-Year average EBITDA Per Share Growth Rate of Rani Therapeutics Holdings was 39.90% per year. The lowest was -41.90% per year. And the median was -5.20% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Rani Therapeutics Holdings 3-Year EBITDA Growth Rate Related Terms
RANI vs ONCY, ALDX, COYA: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Rani Therapeutics Holdings's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rani Therapeutics Holdings 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Rani Therapeutics Holdings's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Rani Therapeutics Holdings's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 39.90% mean?
Rani Therapeutics Holdings (RANI) has a 3-Year EBITDA Growth Rate of 39.90% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Rani Therapeutics Holdings and its competitors. According to the industry distribution chart, Rani Therapeutics Holdings ranks #247 out of 1131 companies in the Biotechnology industry, placing it in the top 21.8%.
Is Rani Therapeutics Holdings' 3-Year EBITDA Growth Rate too high?
Rani Therapeutics Holdings' current 3-Year EBITDA Growth Rate is 39.90%. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.90. Rani Therapeutics Holdings' value of 39.90% is 167.8% above this industry median. Based on the distribution chart, Rani Therapeutics Holdings ranks #247 out of 1131 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Rani Therapeutics Holdings has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Rani Therapeutics Holdings' 3-Year EBITDA Growth Rate compare to ONCY and ALDX?
According to the Biotechnology industry distribution chart, Rani Therapeutics Holdings ranks #247 out of 1131 companies for 3-Year EBITDA Growth Rate. This places Rani Therapeutics Holdings in the top 22% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 14.90. Rani Therapeutics Holdings' value of 39.90% is 167.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.90, based on 1,131 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Rani Therapeutics Holdings's current 3-Year EBITDA Growth Rate of 39.90% is 167.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Rani Therapeutics Holdings and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rani Therapeutics Holdings's current 3-Year EBITDA Growth Rate is 39.90%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rani Therapeutics Holdings stock overvalued right now?
Rani Therapeutics Holdings (RANI) has a current 3-Year EBITDA Growth Rate of 39.90%. The current 3-Year EBITDA Growth Rate is 39.90% and 167.8% above the Biotechnology industry median of 14.90. Rani Therapeutics Holdings' overall GF Score™ is 31/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Rani Therapeutics Holdings (RANI), the current 3-Year EBITDA Growth Rate is 39.90% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.
31GF Score
Get the complete analysis for RANI
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RANI has been successfully added to your 
